Skip to content

Study · Animal study (in vivo) · mouse · 2022

6 results

Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma.

Nevo N, Lee Goldstein A, Bar-David S, Natanson M, Alon G, Lahat G, Nizri E

International immunopharmacology19 Aug 2022Cited by 12 (Europe PMC)

PMID35994852 (opens in a new tab)DOI10.1016/j.intimp.2022.109166 (opens in a new tab)PepBankPUB-35994852
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 after HIPEC increased overall survival compared with HIPEC alone and sham treatment.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 after heated chemotherapy extended survival compared with chemotherapy alone and with sham treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseOverall survival
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone and sham
    Outcome group
    Tumor growth · Cancer
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with Tα1 increased overall survival of mice compared to HIPEC treatment alone and sham-treated animals (16.1 ± 0.8 vs. 14.1 ± 0.6 and 11.8 ± 0.8, respectively, p = 0.02).
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 had no direct anti-tumor effect, as it did not inhibit tumor cell proliferation.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 did not directly slow tumor cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTumor cell proliferation (direct anti-tumor effect)
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone and sham
    Outcome group
    Tumor growth · Cancer
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    Tα1 had no direct anti-tumor effect, as seen by lack of inhibition of tumor cell proliferation.
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 increased the Th1 marker IFN-γ in tumor metastases.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 raised a Th1 immune marker, IFN-γ, in the tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1 marker IFN-γ in metastases
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    Tα1 treatment induced a T helper (Th) 1 immune response in tumor metastases as evidenced by a significant increase of the Th1-specific markers IFN-γ and T-bet (1.21 ± 0.3 vs. 0.52 ± 0.08, p < 0.05; 0.88 ± 0.04 vs. 0.64 ± 0.14, p < 0.05, respectively).
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 increased the Th1 marker T-bet in tumor metastases.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 raised a Th1 immune marker, T-bet, in the tumors.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseTh1 marker T-bet in metastases
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    Tα1 treatment induced a T helper (Th) 1 immune response in tumor metastases as evidenced by a significant increase of the Th1-specific markers IFN-γ and T-bet (1.21 ± 0.3 vs. 0.52 ± 0.08, p < 0.05; 0.88 ± 0.04 vs. 0.64 ± 0.14, p < 0.05, respectively).
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 increased CD8+ T-cell infiltration into omental metastases compared with sham and HIPEC-treated animals.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 brought more CD8+ T cells into omental tumors than sham or chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8+ infiltration into omental metastases
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone and sham
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    This Th1 skew was accompanied by increased CD8+ infiltration into omental and visceral metastases by Tα1 treatment compared to sham and HIPEC-treated animals (21.24 ± 2.16 vs. 10.45 ± 0.89 and 7.7 ± 1.3, p < 0.001; 14.12 ± 1.54 vs. 12.12 ± 0.01 and 6.64 ± 0.87, p < 0.01, respectively).
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with colorectal peritoneal metastases, thymosin alpha‑1 increased CD8+ T-cell infiltration into visceral metastases compared with sham and HIPEC-treated animals.

    In plain wordsIn mice with colon cancer spread in the abdomen, thymosin alpha‑1 brought more CD8+ T cells into organ tumors than sham or chemotherapy alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD8+ infiltration into visceral metastases
    Study

    mousen: not reported in source

    C57BL mice with induced colorectal peritoneal metastases, treated with mitomycin C hyperthermic intraperitoneal chemotherapy (HIPEC)
    Comparator
    HIPEC alone and sham
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.6 mg/kg · 5 days after HIPECAs given in this study (mouse).

    Source sentences

    Summary
    This Th1 skew was accompanied by increased CD8+ infiltration into omental and visceral metastases by Tα1 treatment compared to sham and HIPEC-treated animals (21.24 ± 2.16 vs. 10.45 ± 0.89 and 7.7 ± 1.3, p < 0.001; 14.12 ± 1.54 vs. 12.12 ± 0.01 and 6.64 ± 0.87, p < 0.01, respectively).
    2 context sentences
    Summary · context
    We developed an experimental model of HIPEC by the induction of PM-CRC in C57BL mice and intra-abdominal perfusion of mitomycin C (MMC).
    Summary · context
    Mice were treated with Tα1 at 0.6 mg/kg for 5 days after HIPEC.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.